Compare Adaptive Biotechnologies Corp (ADPT) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Teucrium Soybean Fund — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while Teucrium Soybean Fund trades at $25.05. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Teucrium Soybean Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | SOYB | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $26.28 |
52-Week Low | $12.30 | $21.46 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SOYB trades at $25.05, down 0.48% on the day, with a bearish technical bias from moving averages and neutral oscillators. Key support and resistance cluster at $25. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights agricultural sector volatility from geopolitical tensions and trade developments.
The outlook is clouded by missing financial data, though China's $17 billion U.S. crop purchase pledge through 2028 (Zacks Investment Research, 2026-05-18) offers potential tailwinds. Risks include commodity price swings from Middle East conflicts (24/7 Wall Street, 2026-07-24) and opaque company performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
